American Society of Hematology

ASH is the leader in representing the interests of scientists and clinicians working in the field of hematology on Capitol Hill and within federal agencies concerned with the study and treatment of blood-related diseases.

  • Urge Congress to Pass the SGR Repeal and Medicare Provider Payment Modernization Act and Provide Stable Medicare Physician Payments

    On February 6, 2014 the leadership of the House Ways and Means and Energy and Commerce Committees and the Senate Finance Committee released a bi-partisan and bicameral bill to repeal the Sustainable Growth Rate (SGR) formula that has driven annual reductions in Medicare payment for physician services. Your advocacy is needed to ensure that the legislation can be considered by the full House of Representatives and Senate before the short-term physician fee update expires on April 1, 2014.

  • Take Action to Protect Medical and Public Health Research

    In July, the Senate Appropriations Committee approved a draft spending bill that would provide nearly $31 billion for the National Institutes of Health (NIH) in fiscal year (FY) 2014, an amount that would replace funding lost due to sequestration and provide a small increase over the FY 2012 NIH budget.

View all action alerts
  • Institute of Medicine’s National Cancer Policy Forum Holds a Workshop on Policy Issues in the Development and Adoption of Molecularly Targeted Therapies for Cancer

    ASH staff recently attended an IOM National Cancer Policy Forum workshop on policy issues in the development and adoption of molecularly targeted therapies for cancer.  The purpose of this workshop was to examine the recent trends in the development and implementation of molecularly targeted cancer therapies, address current challenges in the field, and to put forth potential strategies and policy action items that could improve current processes.


  • 2014 ASH Advocacy Efforts Related to Sickle Cell Disease

    ASH remains committed to working with various groups in the sickle cell stakeholder community, Congress, the National Institutes of Health (NIH), the Centers for Disease Control and Prevention (CDC), and other federal agencies to increase research, treatment options, and access to care for patients with sickle cell disease and sickle cell trait.  Continue reading about the major initiatives undertaken by the Society in 2014.

  • 2014 ASH Advocacy Efforts to Ensure Access to Safe and Effective Hematologic Drugs

    Over the past several years, shortages of drugs and biologics used to treat patients with hematologic diseases, including leukemia and lymphoma, have become critical and life-threatening.  ASH has taken a number of steps to resolve these drug and biologic shortages, including working with manufacturers, the Food & Drug Administration (FDA) and Congress.  ASH continues to be actively involved in this issue.  Continue reading for a summary of recent ASH advocacy efforts to address drug and biologic shortages.

  • 2014 NIH Funding Advocacy Highlights

    During 2014, ASH has continued to be one of the most visible advocates for federal support of biomedical research and funding for the National Institutes of Health (NIH).  Continue reading for a summary of ASH's 2014 advocacy efforts.

View all policy news
back to top